Solcon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solcon

Solcon: Definition and Pharmacological Classification

Property Description
Active Ingredient Bromhexine Hydrochloride
Form Tablets, Syrup, Oral Liquid
Pharmacological Class Mucolytic Agent, Expectorant
Common Use Relief of chest congestion and thick mucus
Origin Synthetic organic compound

Solcon is a medicinal product defined by its active component, Bromhexine Hydrochloride, and is classified pharmacologically as both a mucolytic agent and an expectorant. The substance is categorized under the Anatomical Therapeutic Chemical (ATC) code R05CB02, placing it within the group of mucolytics. Bromhexine is a synthetic organic compound, initially developed as a derivative of the alkaloid vasicine, which is historically found in the plant Adhatoda vasica. The proprietary Solcon formulation is clinically recognized for its targeted application in respiratory congestion management and is typically supplied as a single-component product for the oral route of administration.

Composition and General Therapeutic Focus

The primary purpose of Solcon is to assist the body in clearing viscid or excessive mucus from the lower respiratory tract, thereby relieving symptoms of chest congestion often experienced during common respiratory ailments. The drug is available in various common dosage forms, including tablets, syrup, and aqueous oral liquid solutions. The availability of liquid forms addresses the needs of patient groups who require easy-to-swallow preparations. Solcon’s general therapeutic focus is rooted in its secretolytic action: it functions by actively breaking down the complex structural fibers of thick secretions and simultaneously promoting the production of a greater volume of thinner mucus. This process ensures that accumulated phlegm becomes less sticky and more fluid, allowing the body's natural mucociliary clearance mechanisms to expel the mucus more effectively.

Regulatory References

  1. Bromhexine Hydrochloride
  2. mucolytic agent
  3. expectorant
  4. synthetic organic compound
  5. PubChem
  6. viscid or excessive mucus
  7. chest congestion
  8. tablets
  9. syrup
  10. oral liquid

What side effects are possible with Solcon?

Possible Side Effects and Safety Information

The safety profile for Solcon (Bromhexine Hydrochloride) is formally categorized in regulatory documents based on the body systems affected and the reported frequency of adverse events. The primary action of the drug is an expected increase in the flow of mucus secretions.

Officially documented adverse reactions are grouped into frequency tiers. Uncommon side effects (occurring in less than 1 in 100 people) primarily involve the Gastrointestinal system, including nausea, vomiting, diarrhoea, and upper abdominal pain. Rare adverse effects (occurring in less than 1 in 1,000 people) are associated with hypersensitivity reactions and skin effects, such as rash and urticaria.

Classification System-Organ Classes Involved (Examples)
Uncommon Gastrointestinal disorders (Nausea, Diarrhoea)
Rare Skin and subcutaneous tissue disorders (Rash)
Not Known Immune system disorders (Anaphylactic shock)

The most severe, though very rare and categorized as Not Known frequency, are anaphylactic reactions (including shock) and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Should any new skin or mucosal lesions occur, official guidance states that use must be immediately discontinued.

Specific cautions are noted in regulatory information for special populations. The medicine requires particular caution in patients with severe hepatic (liver) or renal (kidney) impairment, as well as those with a history of gastric or peptic ulcers. Use is generally not recommended during the first trimester of pregnancy or while breastfeeding.

Overdose and Emergency Response

The official regulatory profile for Solcon (Bromhexine Hydrochloride) overdose is largely defined by limited clinical data on human overexposure.

Overdose Entity Official Regulatory Summary
Documented Presentations Symptoms are consistent with the known adverse effects of the medicine.
Clinical Signs Manifestations observed in accidental overexposure include headache, nausea, and vomiting.
Overdose Data Status Regulatory records indicate that no specific overdosage symptoms have been reported in humans to date.

Immediate Actions and Supportive Management

In the event of suspected or confirmed overexposure, official guidance strictly mandates that immediate medical assistance must be sought.

Required Emergency Action Supportive Management
Urgent Medical Help is required, necessitating immediate contact with a doctor, pharmacist, or the Poisons Information Centre. Management is restricted to symptomatic treatment to address the presenting clinical signs, as no specific antidote is available.

Overdose Profile Statement

The regulatory description of Solcon overdose is confined by the scarcity of specific data regarding massive overexposure. This constraint dictates that symptoms of overexposure are officially described as mirroring the medicine's mild adverse effects. Consequently, official government guidance requires immediate contact with emergency medical services or poison control when overexposure is suspected, while specifying only supportive care for management. No unique population-specific risks for overdose are noted in the official regulatory documentation.

Therapeutic Uses of Solcon

What Solcon Treats: Main Uses and Benefits

Solcon is primarily used to address symptoms related to impaired airway clearance resulting from the production of overly thick (viscid) and excessive mucus. The therapeutic domain is generally considered relevant for patients with both short-term (acute) and long-term (chronic) diseases of the lungs or airways. The medication's application is generally aimed at easing the symptoms related to thick and persistent phlegm.

It is used in addressing symptom clusters that may become intense or disruptive during acute episodes like acute bronchitis and the chest phase of the common cold, and during recurrent or episodic manifestations of Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis. This supportive action helps ease the overall symptom burden and may assist with maintaining a sense of stability when symptoms are more noticeable.

“The medication may be relevant in contexts involving heightened systemic burden where supportive symptom management is appropriate.”

Solcon is considered relevant when short-term symptomatic assistance is needed to address difficult productive cough and chest congestion, assisting with maintaining functional stability and providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Supportive Management for Viscid and Difficult Phlegm

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population/Condition Regulatory Statement
Contraindicated Children under 6 years of age Must not be used [TGA Monograph]
Contraindicated Known hypersensitivity to Bromhexine Hydrochloride or excipients Prohibited use [HPRA SmPC]
Not Recommended Breastfeeding mothers Should not be used; risk to infant cannot be excluded [HPRA SmPC]
Not Recommended Pregnant women Use is preferable to avoid, especially during the first trimester [HPRA SmPC]

Age-Related Eligibility

Solcon is restricted to adults and adolescents aged 12 years and over for standard use. Use in children aged 6 to 11 years is classified as conditional and is permitted only on the specific advice of a doctor, pharmacist, or nurse practitioner.

Condition-Specific Restrictions (Use with Caution)

Official labeling mandates that the medicine be used with caution in patients with certain pre-existing conditions. These include severe hepatic impairment (liver disease), severe renal impairment (kidney failure), and a history of gastric ulceration or peptic ulceration. Regulatory documents note a lack of specific pharmacokinetic data for the medicine in elderly patients and those with renal or liver insufficiency, further classifying these populations as requiring special consideration. Patients must immediately discontinue use if signs of a severe skin rash are observed.

What should I know about interactions with other medicines?

Solcon Interactions with other medicines and products

The interaction profile for Solcon (Bromhexine Hydrochloride), as documented in official government regulatory documents, is defined by a low incidence of clinically significant adverse interactions, with no medicinal products formally classified as contraindicated combinations. Interaction-related constraints are specified in relation to pharmacodynamic effects, pharmacokinetic exposure, and population-specific clearance.

Official Interaction Statements and Constraints

Interaction Category Officially Documented Constraint or Outcome
Pharmacodynamic Constraint Co-administration with antitussive medications (cough suppressants) is formally cautioned against due to the regulatory-cited risk of accumulation of secretions within the respiratory tract.
Pharmacokinetic Exposure Food intake is documented to cause a specific pharmacokinetic increase in the systemic plasma concentrations of Solcon following ingestion.
Co-administration Outcome The use of Solcon with certain antibiotics (including amoxicillin, erythromycin, and oxytetracycline) is officially associated with an increase in the antibiotic concentration at the site of action, specifically in bronchopulmonary secretions.

Clearance Considerations

Official product information notes that in patient populations with severe hepatic or renal impairment, the natural clearance process for Solcon or its active metabolites may be reduced. This is a documented consideration that could lead to an increase in systemic exposure. No specific timing separation requirements are specified in the regulatory labeling for co-administration with other medicines.

Mechanism of Action

Solcon, a mixture of glycosaminoglycans, primarily targets the vascular endothelium and circulating proteins within the coagulation cascade. It acts as a potentiator of antithrombin III and heparin cofactor II through binding interactions, which collectively accelerates the inactivation of key coagulation factors, including Factor Xa and Factor IIa (thrombin).

Intracellularly, Solcon contributes to an endothelial protective effect by inducing the overexpression of certain local growth factors. Furthermore, it modifies inflammatory processes by influencing the release of inflammatory mediators from macrophages, contributing to an anti-proliferative effect through the regulation of growth factors like VEGF and FGF. Solcon also blocks platelet adhesion and function induced by cathepsin G and thrombin, and mediates an increase in fibrinolytic activity by stimulating the release of tissue plasminogen activator (t-PA) and reducing its endogenous inhibitor, plasminogen activator inhibitor-1 (PAI-1).

The downstream cascade of these molecular interactions results in a multi-pronged anti-thrombotic and vaso-modulatory effect across the systemic circulation.

Dosage and Administration Information

How to Use Solcon (Bromhexine Hydrochloride)

This section outlines the standardized usage patterns for Solcon, defining the approved route, standard dosage ranges, and administration schedule.


Administration and Dosage Patterns

Solcon is formulated exclusively for oral administration, utilizing available forms such as tablets, syrups, and oral solutions. The standard adult dosing regimen for patients 12 years and older typically involves 8 mg taken three times daily.

In some regimens, treatment may begin with an increased dose of up to 16 mg per administration, also taken three times daily, specifically for the initial seven days of therapy, before reducing to the standard 8 mg maintenance dose. The maximum recommended daily intake must not exceed 48 mg.

Age Group Standard Regimen Frequency
Adults (ge 12 years) 8 mg (up to 16 mg initially) Three times daily
Children (6–11 years) 8 mg Three times daily
Children (2–5 years) 4 mg Two or three times daily

Contextual Usage Instructions

Solcon is generally intended for short-term use and should be taken as necessary for the recommended duration. The medicine can typically be taken with or without food. If using an oral liquid or syrup, it is a procedural requirement that the bottle be shaken well before dispensing, and a measuring device must be used to ensure the accuracy of the dose.

Instructions specify that if a dose is missed, the user should skip the missed dose and resume the regular schedule; doubling the dose to compensate is explicitly contrary to standard practice. Furthermore, patients with severe hepatic or renal impairment may require a dose adjustment due to the altered clearance of the active substance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solcon

Evidence for Use in Chronic Bronchitis

Research has examined Solcon in the context of chronic bronchitis, a condition characterized by fluctuating or episodic manifestations. Studies have explored how symptoms evolve in this patient population, monitoring outcomes related to physical discomfort, such as difficulty in clearing the airways. These early studies monitored the physical characteristics of mucus.

Studies observed patterns related to the reported experience of expectoration during the study period. However, because much of the early data was derived from older, smaller trials, evidence quality varies across studies, and findings were mixed regarding definitive, sustained changes in objective outcomes, such as overall ventilatory capacity.

Evidence for Use in Acute Respiratory Ailments

Solcon was also evaluated in research settings for conditions associated with acute or disruptive episodes, such as short-term chest congestion and acute bronchitis. Studies explored temporary physiological imbalance by monitoring outcomes reflecting daily functioning or activity level during the acute illness phase.

Research examined Solcon's use alongside other treatments, such as antibiotics, in specific respiratory conditions characterized by viscid or excessive mucus. Evidence contributes to understanding short-term symptom patterns, with research providing insight into outcomes related to episodic changes. Data show patterns related to how symptoms evolved in the observed populations over defined time intervals during the illness.

What is Still Uncertain About Solcon

The evidence contributes to the broader evidence landscape, but certainty remains low in several areas. The initial research was conducted during an era when stringent methodological approaches were less developed, meaning sample sizes were modest and follow-up durations were limited. This means comparative evidence is lacking against newer treatments, and findings were mixed regarding how the product affects objective breathing measurements.

The available data outline what is known and what remains unstudied. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. CORE BROMHEXINE PRODUCT INFORMATION (Regulatory document providing indication and patient exclusion context)

Frequently Asked Questions (FAQ)

Common questions about Solcon (FAQ)


Q: How long does it typically take for a person to notice the effects of Solcon?

Regulatory pharmacokinetic data describes how quickly the active substance is absorbed by the body. According to this information, the peak concentration of the substance in the bloodstream is generally reached approximately one hour after a person takes a dose by mouth.


Q: What is the usual duration of a single dose's effect?

Official pharmacokinetic reports define the duration of a single dose’s presence in the body through its terminal elimination half-life. The reported half-life, which is the time it takes for half of the active substance to be removed from the body, is generally in the range of 13 to 40 hours.


Q: Are there any specific foods or drinks that should be avoided when using Solcon?

The official product information does not specify any particular foods or beverages that must be avoided while using Solcon. However, regulatory pharmacokinetic data indicates that taking the medicine with food can lead to increased concentrations of the active substance in the bloodstream.


Q: What types of other prescription medicines are known to interact with Solcon?

Official information explicitly mentions interactions with antitussive (cough suppressants) medications and certain antibiotics, including amoxicillin, erythromycin, and oxytetracycline. Co-administration with these antibiotics is associated with an increase in the antibiotic concentration at the site of action.


Q: Is there a list of specific drug classes that should be used with caution alongside Solcon?

Official constraints focus specifically on antitussive medications due to the risk of excess secretion accumulation in the respiratory tract. Furthermore, co-administration with specific antibiotics is detailed, which is associated with an increase in antibiotic concentration in the airways. These specific groups represent the primary documented drug categories mentioned in official product information.


Q: Does Solcon interact with nasal decongestants or cold medicines?

The official label cautions against co-administration with antitussive (cough suppressant) medications. Since antitussives are commonly found in many multi-component cold and flu remedies, this specific warning may apply to those products. The constraint is based on the potential risk of accumulation of secretions in the respiratory tract.


Q: Can Solcon be used by adults over the age of 65?

Official regulatory documents note that there is a lack of specific pharmacokinetic data concerning the use of the medicine in older adults. Use of the medicine requires special consideration in this population, but official documents do not impose restrictions based solely on age. Consideration for use is generally based on the presence of pre-existing conditions, particularly kidney or liver impairment.


Q: Is it common to experience a headache when beginning treatment with Solcon?

According to official safety information, headache is a reported adverse effect that has been listed by regulatory authorities. This symptom is typically classified under nervous system disorders. It is not listed among the most common adverse effects, which are generally gastrointestinal in nature.


Q: Are there any known long-term side effects associated with continuous Solcon use?

Official regulatory documents indicate that Solcon is generally intended for short-term use. Consequently, the official safety profile primarily categorizes reported side effects based on their frequency (e.g., uncommon or rare) observed during short-term trials, rather than differentiating continuous long-term effects.


Q: Can Solcon affect sleep patterns or cause insomnia?

Insomnia is not explicitly listed as a reported adverse effect in official safety documents for Solcon. However, regulatory documents do classify general nervous system disorders, such as dizziness and headache, as reported adverse effects.


Q: Can Solcon cause dizziness or problems with balance?

Dizziness is listed as a reported adverse effect in the official safety documents for Solcon. Regulatory information notes that if reported effects like dizziness are experienced, the ability to drive or operate complex machinery may be impacted.


Q: Are there official warnings about the use of heavy machinery while taking Solcon?

Regulatory documents state that when Solcon is used according to the official dosing regimen, it is generally not known to impair a person's ability to drive or operate machinery. However, this statement is conditional upon not experiencing adverse effects like dizziness or vertigo, which are reported in the safety information.


Q: Is it considered safe to consume alcohol while taking Solcon?

Official safety information indicates that alcohol consumption should be approached with caution while taking Solcon. Since the medicine can cause adverse effects such as dizziness or drowsiness, consuming alcohol may potentially increase the risk or severity of these central nervous system effects.


Q: Is there a concern about interactions if Solcon is taken with other drugs that cause drowsiness?

Official patient information advises caution regarding co-administration with other medicines that may cause drowsiness. Solcon is reported to cause dizziness or general drowsiness in some individuals. Combining it with other central nervous system depressants may increase the likelihood or intensity of these effects.

How should Solcon be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions

Requirement Official Statement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine away from direct sunlight, moisture, and high heat.
Packaging Store in the original container, which is supplied with a child-resistant closure.

Stability and Handling

  • The oral suspension formulation must be discarded 28 days (4 weeks) after the bottle is first opened.
  • Keep all containers tightly closed when not in use.
  • Ensure the product is stored out of the reach of children and pets.

Disposal Rules

Solcon is not on the FDA's list of medicines recommended for flushing. The official disposal procedures are:

  1. Preferred Method: Utilize a local drug take-back program or authorized collection site.
  2. Household Trash: If a take-back program is unavailable, mix the unused medicine with an unappealing substance (like dirt or coffee grounds) and place the mixture in a sealed plastic bag before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solcon found in:

A-Z Index: